Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study

James W. Smithy; Hannah L. Kalvin; Fiona Ehrich; Ronak Shah; Matthew Adamow; Vladislav Raber; Collen A. Maher; Jenna Kleman; Deborah A.G. McIntyre; Alexander N. Shoushtari; Allison Betof Warner; Margaret K. Callahan; Parisa Momtaz; Omar Eton; Suresh Nair; Jedd D. Wolchok; Paul B. Chapman; Michael F. Berger; Katherine S. Panageas; Michael A. Postow

doi:10.1158/1078-0432.ccr-23-3643

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment. Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi). Exploratory biomarker analyses and final clinical results are now reported.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Smithy et al. (2024) studied this question.

synapsesocial.com/papers/68e69377b6db64358761a9a1 https://doi.org/10.1158/1078-0432.ccr-23-3643

View at Publisher

Ask AI

Bookmark

Share

Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study

Ask about this paper

Abstract

Discussion

Cite This Study

Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading